TheraVac-01: Evaluation of Safety and Immunogenicity of the HIV-1 Vaccine NYVAC-B in Chronic HIV-1 Infected Patients Successfully Treated with HAART

被引：0
|
作者：
Bart, P-A [1 ]
Harari, A. [1 ]
Vermeulen, J. N. [2 ,3 ]
Enders, F. Bellutti [1 ]
Bataenjer, E. Castro [1 ]
Cavassini, M. [1 ]
Wit, F. W. [2 ,3 ]
Autran, B. [4 ]
Lange, J. M. [2 ,3 ]
Pantaleo, G. [1 ]
机构：
[1] CHU Vaudois, Lausanne, Switzerland
[2] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] IATEC, Amsterdam, Netherlands
[4] Fac Med Pierre & Marie Curie, Paris, France
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2008年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [31] Headache in HIV-1 infected patients
    De Marinis, M.
    Fimiani, C.
    Li Voti, P.
    Fantauzzi, A.
    Colaizzo, E.
    CEPHALALGIA, 2006, 26 (11) : 1379 - 1379
  • [32] Legionellosis in HIV-1 infected patients
    Sène, D
    Bossi, P
    Thomas, L
    Ghosn, J
    Zeller, V
    Caumes, E
    Katlama, C
    Bricaire, F
    PRESSE MEDICALE, 2002, 31 (08): : 356 - 358
  • [33] The effect of HAART on humoral immune response in primary HIV-1 infected patients
    Pastori, C
    Barassi, C
    Lillo, F
    Longhi, R
    Capiluppi, B
    Nozza, S
    Galli, A
    Uberti-Foppa, C
    Lazzarin, A
    Tambussi, G
    Lopalco, L
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2002, 16 (01): : 9 - 17
  • [34] Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees
    Bagarazzi, ML
    Boyer, JD
    Ugen, KE
    Javadian, MA
    Chattergoon, M
    Shah, A
    Bennett, M
    Ciccarelli, R
    Carrano, R
    Coney, L
    Weiner, DB
    VACCINE, 1998, 16 (19) : 1836 - 1841
  • [35] DETECTION OF HIV-1 RNA IN EPIDERMAL LANGERHANS CELLS OF HIV-1 INFECTED PATIENTS
    GIROLOMONI, G
    ZAMBRUNO, G
    CIMARELLI, A
    MARCONI, A
    NEGRONI, M
    BERTAZZONI, U
    GIANNETTI, A
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 100 (04) : 443 - 443
  • [36] Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients
    Söderlund, J
    Hirbod, T
    Goh, LE
    Andersson, J
    Broliden, K
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (09) : 663 - 669
  • [37] Safety and Immunogenicity of a Multiclade HIV-1 DNA Vaccine Boosted by a Multiclade HIV-1 Ad5 Vaccine in HIV-Uninfected Adult Subjects (HVTN 204)
    Churchyard, G. J.
    Morgan, C.
    Keefer, M.
    Adams, E.
    Hural, J.
    Graham, B.
    Moodie, Z.
    Gray, G.
    Vardas, E.
    Bekker, L.
    McElrath, M. J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 18 - 18
  • [38] HIV-1/HIV-2 SERONEGATIVITY IN HIV-1 SUBTYPE-O INFECTED PATIENTS
    LOUSSERTAJAKA, I
    BRUNVEZINET, F
    SIMON, F
    LY, TD
    CHAIX, ML
    SARAGOSTI, S
    COUROUCE, AM
    INGRAND, D
    LANCET, 1994, 343 (8910): : 1393 - 1394
  • [39] Sub-optimal response to HAART in patients treated at time of primary HIV-1 infection and infected with HIV resistant strains
    Chaix, ML
    Desquilbet, L
    Cottalorda, J
    Descamps, D
    Deveau, C
    Galimand, J
    Goujard, C
    Harzic, M
    Masquelier, B
    Pellegrin, I
    Ruffault, A
    Schneider, V
    Tamalet, C
    Wirden, M
    Costagliola, D
    Brun-Vezinet, F
    Rouzioux, C
    Meyer, L
    ANTIVIRAL THERAPY, 2005, 10 : S127 - S127
  • [40] Sub-optimal response to HAART in patients treated at time of primary HIV-1 infection and infected with HIV resistant strains
    Chaix, ML
    Desquilbet, L
    Cottalorda, J
    Descamps, D
    Deveau, C
    Galimand, J
    Goujard, C
    Harzic, M
    Masquelier, B
    Pellegrin, I
    Ruffault, A
    Schneider, V
    Tamalet, C
    Wirden, M
    Costagliola, D
    Brun-Vezinet, F
    Rouzioux, C
    Meyer, L
    ANTIVIRAL THERAPY, 2005, 10 (04) : S127 - S127
12345